Unilife Corp. has signed a clinical development and supply agreement with a global pharmaceutical company for a novel device for targeted organ delivery. The Unilife device will be used in a clinical trial scheduled to begin in early 2012. Unilife will receive $1.4 million in development fees and revenue from initial unit sales of the devices for this and future clinical trials. Unilife’s chief operating officer, Dr. Ramin Mojdeh, said, “This partnership demonstrates Unilife’s capability in dev...